Fate Therapeutics weighs cell pipeline against losses
Fate Therapeutics has a broad CAR T-cell and NK-cell pipeline alongside negative free cash flow. Its supplied market snapshot lists $153.77 million in cash, while separate second-quarter figures report $32.429 million at June 30, 2026.